{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:14Z","timestamp":1790842094745,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Impairment in cognition and decline in kidney function often converge in the aging individual with chronic kidney disease (CKD). Cognitive impairment (CI) may be preventable through modification of health behaviors and risk factors that contribute to the vascular disease burden. CKD patients often have multiple coexisting comorbid conditions contributing to vascular risk. These comorbidities include hypertension, diabetes, cerebrovascular disease, and cardiovascular disease. Emerging evidence suggests that the management and prevention of vascular risk factors and cardiovascular diseases may indirectly contribute to the prevention of CI in CKD. Sodium glucose transport protein 2 inhibitors (SGLT2i) are emerging as the standard of care for selected individuals with CKD, type 2 diabetes (T2DM), and heart failure with rapidly expanding indications being actively investigated. In this narrative review, we examine the intriguing hypothesis that SGLT2i demonstrate potential disease modifying properties in CI among individuals with CKD.<\/jats:p>","DOI":"10.3389\/fneur.2022.823569","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T06:08:24Z","timestamp":1655791704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD"],"prefix":"10.3389","volume":"13","author":[{"given":"J. Ariana","family":"Noel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hougen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105529","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105529","article-title":"Chronic kidney disease and cognitive impairment","volume":"30","author":"Murtaza","year":"2021","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41581-020-0266-9","article-title":"Mechanisms of cognitive dysfunction in CKD","volume":"16","author":"Viggiano","year":"2020","journal-title":"Nat Rev Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1532-5415.2009.02670.x","article-title":"Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study","volume":"58","author":"Yaffe","year":"2010","journal-title":"J Am Geriatr Soc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","volume":"99","author":"Kidney","year":"2021","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000502446","article-title":"Mechanisms of stroke in patients with chronic kidney disease","volume":"50","author":"Ghoshal","year":"2019","journal-title":"Am J Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.3233\/JAD-180498","article-title":"Associations of chronic kidney disease markers with cognitive function: a 12-year follow-up study","volume":"70","author":"Sacre","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: core curriculum 2018","volume":"71","author":"Umanath","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1017\/S1355617718000917","article-title":"A systematic review of cognitive impairments associated with kidney failure in adults before natural age-related changes","volume":"25","author":"Brodski","year":"2019","journal-title":"J Int Neuropsychol Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.ajkd.2019.05.017","article-title":"Cognitive impairment in CKD: pathophysiology, management, and prevention","volume":"74","author":"Drew","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.acn.2004.11.004","article-title":"Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS","volume":"20","author":"Tombaugh","year":"2005","journal-title":"Arch Clin Neuropsychol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/ndt\/gfs470","article-title":"Decline in renal functioning is associated with longitudinal decline in global cognitive functioning, abstract reasoning and verbal memory","volume":"28","author":"Davey","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1474-4422(14)70026-2","article-title":"Stroke and cerebrovascular diseases in patients with chronic kidney disease","volume":"13","author":"Toyoda","year":"2014","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ki.2010.336","article-title":"Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies","volume":"79","author":"Kurella Tamura","year":"2011","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2215\/CJN.01960215","article-title":"Frailty and cognitive function in incident hemodialysis patients","volume":"10","author":"McAdams-DeMarco","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1161\/STROKEAHA.110.581215","article-title":"Impact of microalbuminuria on incident stroke: a meta-analysis","volume":"41","author":"Lee","year":"2010","journal-title":"Stroke."},{"key":"B18","doi-asserted-by":"publisher","first-page":"c4249","DOI":"10.1136\/bmj.c4249","article-title":"Low glomerular filtration rate and risk of stroke: meta-analysis","volume":"341","author":"Lee","year":"2010","journal-title":"BMJ."},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: the ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Arch Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3233\/JAD-189008","article-title":"Albuminuria and Microalbuminuria as predictors of cognitive performance in a general population: an 11-year follow-up study","volume":"65","author":"Ekblad","year":"2018","journal-title":"J Alzheimers Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/jgs.14750","article-title":"Albuminuria in association with cognitive function and dementia: a systematic review and meta-analysis","volume":"65","author":"Georgakis","year":"2017","journal-title":"J Am Geriatr Soc."},{"key":"B22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1053\/j.ajkd.2016.04.017","article-title":"Estimated GFR, albuminuria, and cognitive performance: the maastricht study","volume":"69","author":"Martens","year":"2017","journal-title":"Am J Kidney Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1053\/j.ajkd.2020.03.015","article-title":"Albuminuria and estimated GFR as risk factors for dementia in midlife and older age: findings from the ARIC study","volume":"76","author":"Scheppach","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cjca.2019.11.036","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O'Meara","year":"2020","journal-title":"Can J Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology solution set oversight committee","volume":"77","author":"Writing","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert","year":"2018","journal-title":"Can J Diabetes."},{"key":"B34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care."},{"key":"B35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension."},{"key":"B36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s12020-017-1301-x","article-title":"Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? a retrospective case series","volume":"59","author":"Chilelli","year":"2018","journal-title":"Endocrine."},{"key":"B37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1590\/1806-9282.65.1.70","article-title":"Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy","volume":"65","author":"Cintra","year":"2019","journal-title":"Rev Assoc Med Bras."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 Inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and australian spontaneous adverse event notifications","volume":"41","author":"Meyer","year":"2018","journal-title":"Diabetes Care."},{"key":"B39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","article-title":"Canagliflozin and stroke in type 2 diabetes mellitus","volume":"50","author":"Zhou","year":"2019","journal-title":"Stroke."},{"key":"B41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE Trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation."},{"key":"B42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2174\/18715273113126660160","article-title":"Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study","volume":"13","author":"Rizvi","year":"2014","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"B43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/bab.1319","article-title":"Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders","volume":"63","author":"Shaikh","year":"2016","journal-title":"Biotechnol Appl Biochem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol Appl Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/bs.irn.2020.03.018","article-title":"A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?","volume":"155","author":"Esterline","year":"2020","journal-title":"Int Rev Neurobiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Tsai","year":"2021","journal-title":"Sci Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2337\/dc21-2434","article-title":"Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction","volume":"45","author":"Mone","year":"2022","journal-title":"Diabetes Care."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e045844","DOI":"10.1136\/bmjopen-2020-045844","article-title":"Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes","volume":"11","author":"Yabe","year":"2021","journal-title":"BMJ Open."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.823569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T06:08:26Z","timestamp":1655791706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.823569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":51,"alternative-id":["10.3389\/fneur.2022.823569"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.823569","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"article-number":"823569"}}